CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
| 대상 질환 | Acute Lymphoblastic Leukemia |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | M.D. Anderson Cancer Center |
| 상태 | 완료 |
| 참여자 수 | 90 명 |
| 중재(약물) | CMC-544 (Inotuzumab Ozogamycin), Rituximab |
| 시작일 | 2010년 6월 4일 |
| 완료일 | 2018년 4월 18일 |
| 결과 공개일 | 2019년 5월 22일 |
요약
The goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.
Number of Patients With Response
| Period 1: CMC-544 (Inotuzumab Ozogamycin) 1.3mg/m^2 | 3 Participants |
|---|---|
| Period 2: CMC-544 (Inotuzumab Ozogamycin) 1.8mg/m^2 | 25 Participants |
| Period 3: Weekly CMC-544 (Inotuzumab Ozogamycin) | 24 Participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diag — National Cancer Institute (NCI)
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Tr — National Cancer Institute (NCI)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibruti — National Cancer Institute (NCI)
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituxim — National Cancer Institute (NCI)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual — National Cancer Institute (NCI)
- Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute — Wake Forest University Health Sciences